Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study
Romina Tejada, Armando Baena, Lina Trujillo, Juliana Rodriguez, Mathieu Maheu-Giroux, Maribel Almonte, Eduardo L. Franco, Talía Malagón · 2026
Read Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study by Romina Tejada, Armando Baena, Lina Trujillo, Juliana Rodriguez, Mathieu Maheu-Giroux, Maribel Almonte, Eduardo L. Franco, Talía Malagón (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13158420.txt.
Description
Eight authors model a vaccine switch in Colombia in 2026, from a four-type HPV vaccine to a nine-type one. Cervical cancer struck 13.7 per 100,000 women in 2022, and girl cover sits near 51 percent. A spread model tracks the virus by age, sex, and vaccine state across the whole country.
At current cover, the nine-type shot cut virus spread in women by about 39 percent by 2100 in the model. Raising the four-type shot to 90 percent cover cut spread by only about eight percent. Only the nine-type path drove cancer rates under the goal line, as early as 2058.
Catalog record
| CREATOR | Romina Tejada, Armando Baena, Lina Trujillo, Juliana Rodriguez, Mathieu Maheu-Giroux, Maribel Almonte, Eduardo L. Franco, Talía Malagón |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |